{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:51:40Z","timestamp":1765057900429,"version":"3.41.2"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oral. Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anticoagulants, renowned for their role in preventing blood clot formation, have captivated researchers\u2019 attention for the exploitation of their potential to inhibit cancer in pre-clinical models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To undertake a systematic review and meta-analysis of the effects of anticoagulants in murine cancer research models. Further, to present a reference tool for anticoagulant therapeutic modalities relating to future animal pre-clinical models of cancer and their translation into the clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four databases were utilized including Medline (Ovid), Embase (Ovid), Web of science, and Scopus databases. We included studies relating to any cancer conducted in murine models that assessed the effect of traditional anticoagulants (heparin and its derivatives and warfarin) and newer oral anticoagulants on cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 6,158 articles were identified in an initial multi-database search. A total of 157 records were finally included for data extraction. Studies on heparin species and warfarin demonstrated statistically significant results in favour of tumour growth and metastasis inhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings constitute a valuable reference guide for the application of anticoagulants in cancer research and explore the promising utilization of non-anticoagulants heparin in preclinical cancer research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO [CRD42024555603].<\/jats:p><\/jats:sec>","DOI":"10.3389\/froh.2024.1495942","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T06:12:32Z","timestamp":1730873552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"5","author":[{"given":"Huda Moutaz Asmael","family":"Al-Azzawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ameer","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fizza","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romeo","family":"Patini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Celentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"volume-title":"WHO Global Survey on the Inclusion of Cancer Care in Health-Benefit Packages, 2020\u20132021","year":"2024","key":"B2"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5426974","DOI":"10.1155\/2019\/5426974","article-title":"Recent advances in identifying biomarkers and high-affinity aptamers for gynecologic cancers diagnosis and therapy","volume":"2019","author":"Ma","year":"2019","journal-title":"J Anal Methods Chem"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26444\/aaem\/94299","article-title":"Environmental risk factors for cancer\u2014review paper","volume":"26","author":"Lewandowska","year":"2019","journal-title":"Ann Agric Environ Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20503121211034366","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41568-023-00568-4","article-title":"Dissecting metastasis using preclinical models and methods","volume":"23","author":"Hebert","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1538-7836.2011.04346.x","article-title":"Management of venous thromboembolism in patients with cancer","volume":"9","author":"Agnelli","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/S0049-3848(10)70017-7","article-title":"Antimetastatic activities of heparins and modified heparins. Experimental evidence","volume":"125","author":"Borsig","year":"2010","journal-title":"Thromb Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.thromres.2019.12.022","article-title":"A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models","volume":"187","author":"Najidh","year":"2020","journal-title":"Thromb Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/sj.bjc.6603120","article-title":"Targeting lymphangiogenesis to prevent tumour metastasis","volume":"94","author":"Achen","year":"2006","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fcvm.2015.00030","article-title":"Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art","volume":"2","author":"Thaler","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.medcli.2017.11.042","article-title":"Anticoagulantes orales directos: puesta al d\u00eda","volume":"151","author":"Franco Moreno","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1158\/0008-5472.CAN-14-2887-T","article-title":"Warfarin blocks Gas6-mediated axl activation required for pancreatic cancer epithelial plasticity and metastasis","volume":"75","author":"Kirane","year":"2015","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3390\/cancers12051144","article-title":"Direct oral anticoagulants in cancer patients. Time for a change in paradigm","volume":"12","author":"Wojtukiewicz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/apm.1965.65.3.395","article-title":"Action of heparin and plasminogen inhibitor (EACA) on metastatic tumour spread in an isologous system","volume":"65","author":"Boeryd","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"B19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/apm.1966.68.3.347","article-title":"Effect of heparin and plasminogen inhibitor (EACA) in brief and prolonged treatment on intravenously injected tumour cells","volume":"68","author":"Boeryd","year":"1966","journal-title":"Acta Pathol Microbiol Scand"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1699-0463.1967.tb05123.x","article-title":"Effect of heparin, plasminogen inhibitor (EACA) and trauma on tumour metastases","volume":"69","author":"Boeryd","year":"1967","journal-title":"Acta Pathol Microbiol Scand"},{"key":"B21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1699-0463.1970.tb00248.x","article-title":"Tumour growth and spontaneous metastasis spread in two syngeneic systems","volume":"78","author":"Hagmar","year":"1970","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ijc.2910050110","article-title":"Evidence for effects of heparin on cell surfaces influencing experimental metastases","volume":"5","author":"Hagmar","year":"1970","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/1097-0142(196404)17:4%3C450::AID-CNCR2820170406%3E3.0.CO;2-2","article-title":"Mechanism of blood-borne metastases. I. Some factors affecting lodgment and growth of tumor cells in the lungs","volume":"17","author":"Koike","year":"1964","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/ijc.22424","article-title":"Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines","volume":"120","author":"Monzavi-Karbassi","year":"2007","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF00397719","article-title":"Combined immunostimulation (Propionibacterium avidum KP 40) and anticoagulation (heparin) prevents metastatic lung and liver colonization in mice","volume":"113","author":"Beuth","year":"1987","journal-title":"J Cancer Res Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF00117789","article-title":"Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid","volume":"8","author":"Lee","year":"1990","journal-title":"Clin Exp Metastasis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3171\/jns.1990.73.3.0429","article-title":"Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone","volume":"73","author":"Lee","year":"1990","journal-title":"J Neurosurg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/BF01784377","article-title":"Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin","volume":"6","author":"Lee","year":"1988","journal-title":"Clin Exp Metastasis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0309-1651(78)90087-5","article-title":"The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice","volume":"2","author":"Lione","year":"1978","journal-title":"Cell Biol Int Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1349-7006.1989.tb01728.x","article-title":"Inhibitory effect of chitin heparinoids on the lung metastasis of B16-BL6 melanoma","volume":"80","author":"Murata","year":"1989","journal-title":"Jpn J Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1538-7836.2006.01793.x","article-title":"Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice","volume":"4","author":"Rossi","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B32","first-page":"2869","article-title":"Effect of fraxiparine and heparin on experimental tumor metastasis in mice","volume":"25","author":"Szende","year":"2005","journal-title":"Anticancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/0014-2964(77)90170-0","article-title":"Proteases during the growth of ehrlich ascites tumor. III. Effect of e-aminocaproic acid (EACA) and heparin","volume":"13","author":"Back","year":"1977","journal-title":"Eur J Cancer (1965)"},{"key":"B34","first-page":"357","article-title":"Cell surface charge and metastasis formation. A study on the effects of dextrans and heparin on tumour cells and experimental metastases in a syngeneic murine system","volume":"80","author":"Hagmar","year":"1972","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/cncr.26518","article-title":"Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma","volume":"118","author":"Ichikawa","year":"2012","journal-title":"Cancer"},{"key":"B36","first-page":"22","article-title":"Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives","volume":"51","author":"Murata","year":"1991","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/0006-2952(83)90110-7","article-title":"Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells","volume":"32","author":"Colucci","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0268-9499(92)90091-U","article-title":"Protective effect of fibrin on tumour metastasis","volume":"6","author":"Gorelik","year":"1992","journal-title":"Fibrinolysis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1073\/pnas.261704098","article-title":"Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis","volume":"99","author":"Borsig","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-2002-34308","article-title":"Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide","volume":"28","author":"Poggi","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0065-2571(97)00016-2","article-title":"Cancer cell heparanase activity associated with invasion and metastasis","volume":"38","author":"Nicolson","year":"1998","journal-title":"Adv Enzyme Regul"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2014.04.016","article-title":"Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin","volume":"350","author":"Sudha","year":"2014","journal-title":"Cancer Lett"},{"key":"B43","first-page":"809","article-title":"Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice","volume":"47","author":"Gorelik","year":"1987","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3892\/or.3.1.219","article-title":"Antimetastatic effects associated with anticoagulant properties of heparin and chemically modified heparin species in a mouse mammary tumor model","volume":"3","author":"Alonso","year":"1996","journal-title":"Oncol Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10585-005-3859-6","article-title":"Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest","volume":"22","author":"Bereczky","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.lungcan.2004.06.012","article-title":"Anticoagulant drugs increase natural killer cell activity in lung cancer","volume":"47","author":"Bobek","year":"2005","journal-title":"Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1699-0463.1972.tb00284.x","article-title":"Disappearance of circulating tumour cells in mice treated with heparin, coumarin and EACA","volume":"80","author":"Boeryd","year":"1972","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1073\/pnas.061615598","article-title":"Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis","volume":"98","author":"Borsig","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.ijbiomac.2018.06.143","article-title":"Anti-IIa activity and antitumor properties of a hybrid heparin\/heparan sulfate-like compound from litopenaeus vannamei shrimp","volume":"118","author":"Brito","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/archsurg.1965.01320160079018","article-title":"Increased incidence of pulmonary metastases after celiotomy: counteraction by heparin","volume":"91","author":"el Rifi","year":"1965","journal-title":"Arch Surg"},{"key":"B51","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3181\/00379727-107-26771","article-title":"Growth characteristics of ascitic tumor cells in the heparinized peritoneal cavity of the mouse","volume":"107","author":"Goldie","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/end.1993.7.237","article-title":"Inhibition of peritoneal tumor-cell implantation: model for laparoscopic cancer surgery","volume":"7","author":"Goldstein","year":"1993","journal-title":"J Endourol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ijc.2910330115","article-title":"Role of NK cells in the antimetastatic effect of anticoagulant drugs","volume":"33","author":"Gorelik","year":"1984","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-06-1987","article-title":"Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids?","volume":"13","author":"Harvey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1021\/bi00366a050","article-title":"Chemically modified heparins as inhibitors of heparan sulfate specific endo-.beta.-glucuronidase (heparanase) of metastatic melanoma cells","volume":"25","author":"Irimura","year":"1986","journal-title":"Biochemistry"},{"key":"B56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.115.2980.145","article-title":"Effect of heparin on the growth of a transplantable lymphosarcoma in mice","volume":"115","author":"Kreisler","year":"1952","journal-title":"Science"},{"key":"B57","first-page":"11","article-title":"The growth-inhibitory action of heparin on the ehrlich ascites tumor in mice","volume":"17","author":"Lippman","year":"1957","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1160\/TH05-07-0515","article-title":"The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo","volume":"95","author":"Ludwig","year":"2006","journal-title":"Thromb Haemost"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-03-1054","article-title":"Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s10637-010-9578-0","article-title":"Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer","volume":"30","author":"Ma","year":"2012","journal-title":"Invest New Drugs"},{"key":"B61","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/bjc.1978.56","article-title":"Extrapulmonary colony formation after intravenous injection of tumour cells into heparin-treated animals","volume":"37","author":"Maat","year":"1978","journal-title":"Br J Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00410113","article-title":"Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems","volume":"101","author":"Maat","year":"1981","journal-title":"J Cancer Res Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.bjc.6603928","article-title":"Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo","volume":"97","author":"Mellor","year":"2007","journal-title":"Br J Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF01585080","article-title":"Treatment with cortisone plus heparin or hexuronyl hexoaminoglycan sulfates of murine tumors and their lung deposits","volume":"3","author":"Milas","year":"1985","journal-title":"Clin Exp Metastasis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1349-7006.1990.tb02599.x","article-title":"Inhibition of tumor cell arrest in lungs by antimetastatic chitin heparinoid","volume":"81","author":"Murata","year":"1990","journal-title":"Jpn J Cancer Res"},{"key":"B66","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/1097-0142(19911015)68:8<1724::AID-CNCR2820680813>3.0.CO;2-W","article-title":"Inhibition of tumor implantation at sites of trauma by plasminogen activators","volume":"68","author":"Murthy","year":"1991","journal-title":"Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/aps.2012.42","article-title":"Roles of vimentin and 14-3-3 zeta\/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis","volume":"33","author":"Pan","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1016\/j.biomaterials.2007.02.001","article-title":"The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative","volume":"28","author":"Park","year":"2007","journal-title":"Biomaterials"},{"key":"B69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11095-006-9139-6","article-title":"Antiangiogenic effect of bile acid acylated heparin derivative","volume":"24","author":"Park","year":"2006","journal-title":"Pharm Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11095-007-9366-5","article-title":"Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma","volume":"25","author":"Park","year":"2008","journal-title":"Pharm Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0148454","DOI":"10.1371\/journal.pone.0148454","article-title":"Application of a persistent heparin treatment inhibits the malignant potential of oral squamous carcinoma cells induced by tumor cell-derived exosomes","volume":"11","author":"Sento","year":"2016","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"26616","DOI":"10.1074\/jbc.M111.224212","article-title":"Heparin impairs angiogenesis through inhibition of microRNA-10b","volume":"286","author":"Shen","year":"2011","journal-title":"J Biol Chem"},{"key":"B73","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins\u2014correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/S0049-3848(07)70138-X","article-title":"Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects","volume":"120","author":"Stevenson","year":"2007","journal-title":"Thromb Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3109\/08923979009019667","article-title":"Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin","volume":"12","author":"Sylvester","year":"1990","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.bjp.0706344","article-title":"A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity","volume":"146","author":"Takahashi","year":"2005","journal-title":"Br J Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bjc.1991.382","article-title":"Anticoagulant treatment does not affect the action of flavone acetic acid in tumour-bearing mice","volume":"64","author":"Thurston","year":"1991","journal-title":"Br J Cancer"},{"key":"B78","first-page":"10","article-title":"Heparin inhibits P388D1 cells adherence and metastasis to peripheral lymph nodes in vitro and in vivo","volume":"42","author":"Wei","year":"2009","journal-title":"Lymphology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/2021348a0","article-title":"Influence of various substances on production of ascites tumour","volume":"202","author":"Wheatley","year":"1964","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10585-008-9212-0","article-title":"Inhibition of osteolytic bone metastasis by unfractionated heparin","volume":"25","author":"Yee","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3892\/etm.2014.1911","article-title":"Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice","volume":"8","author":"Yin","year":"2014","journal-title":"Exp Ther Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2003.11.037","article-title":"Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity","volume":"207","author":"Yoshitomi","year":"2004","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/156800910791054176","article-title":"Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats","volume":"10","author":"Yu","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/ijc.24561","article-title":"Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo","volume":"125","author":"Zhang","year":"2009","journal-title":"Int J Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1158\/1078-0432.CCR-07-0641","article-title":"Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis","volume":"14","author":"Lee","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"075102","DOI":"10.1088\/1361-6528\/aa53c6","article-title":"Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin","volume":"28","author":"Cheng","year":"2017","journal-title":"Nanotechnology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"27544","DOI":"10.1038\/srep27544","article-title":"Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase","volume":"6","author":"Luengo-Gil","year":"2016","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e41035","DOI":"10.1371\/journal.pone.0041035","article-title":"Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation","volume":"7","author":"Niu","year":"2012","journal-title":"PLoS One"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1021\/acs.molpharmaceut.5b00348","article-title":"Chemical conjugate of low molecular weight heparin and suramin fragment inhibits tumor growth possibly by blocking VEGF165","volume":"12","author":"Park","year":"2015","journal-title":"Mol Pharm"},{"key":"B90","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jconrel.2010.09.014","article-title":"High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives","volume":"148","author":"Park","year":"2010","journal-title":"J Control Release"},{"key":"B91","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/cas.12133","article-title":"Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells","volume":"104","author":"Takeuchi","year":"2013","journal-title":"Cancer Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1038\/s41598-020-64561-9","article-title":"Compound opening arrow mixture exerts anti-tumor effects in a mouse model of breast cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Sci Rep"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1055\/s-0042-1745743","article-title":"Pharmacokinetic, hemostatic, and anticancer properties of a low-anticoagulant bovine heparin","volume":"6","author":"Santos","year":"2022","journal-title":"TH Open"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1046\/j.1538-7836.2003.00341.x","article-title":"Antimetastatic effect of tinzaparin, a low-molecular-weight heparin","volume":"1","author":"Amirkhosravi","year":"2003","journal-title":"J Thromb Haemost"},{"key":"B95","first-page":"411","article-title":"Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin","volume":"31","author":"Phillips","year":"2011","journal-title":"Anticancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3892\/ijo.2014.2803","article-title":"Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models","volume":"46","author":"Alyahya","year":"2015","journal-title":"Int J Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/SLA.0b013e31826fcbdb","article-title":"Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model","volume":"258","author":"Seth","year":"2013","journal-title":"Ann Surg"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1182\/blood.2020005710","article-title":"Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model","volume":"137","author":"Feinauer","year":"2021","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1182\/blood-2014-08-595686","article-title":"von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans","volume":"125","author":"Bauer","year":"2015","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"68527","DOI":"10.18632\/oncotarget.11832","article-title":"Heparins that block VEGF-A-mediated von willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis","volume":"7","author":"Goertz","year":"2016","journal-title":"Oncotarget"},{"key":"B101","first-page":"99","article-title":"Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth","volume":"14","author":"Kragh","year":"2005","journal-title":"Oncol Rep"},{"key":"B102","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/molecules22050728","article-title":"The impact of the low molecular weight heparin tinzaparin on the sensitization of cisplatin-resistant ovarian cancers-preclinical in vivo evaluation in Xenograft tumor models","volume":"22","author":"Mueller","year":"2017","journal-title":"Molecules"},{"key":"B103","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.3390\/ijms22137053","article-title":"Combinatorial treatment of tinzaparin and chemotherapy can induce a significant antitumor effect in pancreatic cancer","volume":"22","author":"Sarantis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.thromres.2014.02.020","article-title":"The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin","volume":"133","author":"Schlesinger","year":"2014","journal-title":"Thromb Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"S985","DOI":"10.4103\/0973-1482.192765","article-title":"Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model","volume":"14","author":"Rui","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jth.14443","article-title":"The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice","volume":"17","author":"Buijs","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B107","doi-asserted-by":"publisher","first-page":"eaaw8405","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell-synthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1476-5586(03)80007-6","article-title":"Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin","volume":"5","author":"Lund","year":"2003","journal-title":"Neoplasia"},{"key":"B109","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.thromres.2009.03.005","article-title":"Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver","volume":"125","author":"Klerk","year":"2010","journal-title":"Thromb Res"},{"key":"B110","first-page":"70","article-title":"Comparison of the effects of enoxaparin and nadroparin on tumor angiogenesis in mice","volume":"31","author":"Wasiutynski","year":"2006","journal-title":"Cent Eur J Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.2147\/OTT.S176526","article-title":"Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models","volume":"11","author":"Zhuang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B112","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10585-008-9227-6","article-title":"Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung","volume":"26","author":"Niers","year":"2009","journal-title":"Clin Exp Metastasis"},{"key":"B113","first-page":"77","article-title":"Experimental immunology sarcoma L-1 in mice as a model for the study of experimental angiogenesis","volume":"32","author":"Skopi\u0144ska-R\u00f3\u017cewska","year":"2007","journal-title":"Cent Eur J Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1160\/th06-05-0289","article-title":"Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin","volume":"96","author":"Mousa","year":"2006","journal-title":"Thromb Haemost"},{"key":"B115","first-page":"4019","article-title":"Enoxaparin attenuates mouse colon cancer liver metastases by inhibiting heparanase and interferon-\u03b3-inducible chemokines","volume":"36","author":"Djaafar","year":"2016","journal-title":"Anticancer Res"},{"key":"B116","first-page":"37","article-title":"Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells","volume":"59","author":"Stocking","year":"2009","journal-title":"Comp Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e11200","DOI":"10.1371\/journal.pone.0011200","article-title":"A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx","volume":"5","author":"Van Sluis","year":"2010","journal-title":"PLoS One"},{"key":"B118","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1158\/1541-7786.MCR-11-0482","article-title":"Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis","volume":"10","author":"Pollari","year":"2012","journal-title":"Mol Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1535-7163.MCT-18-0417","article-title":"Necuparanib, a multitargeting heparan sulfate mimetic, targets tumor and stromal compartments in pancreatic cancer","volume":"18","author":"MacDonald","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2007.07.017","article-title":"Glucosylated heparin derivatives as non-toxic anti-cancer drugs","volume":"123","author":"Lee","year":"2007","journal-title":"J Control Release"},{"key":"B121","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.canlet.2017.12.009","article-title":"Supersulfated low-molecular weight heparin synergizes with IGF1R\/IR inhibitor to suppress synovial sarcoma growth and metastases","volume":"415","author":"Cassinelli","year":"2018","journal-title":"Cancer Lett"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1002\/ijc.24239","article-title":"Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor","volume":"124","author":"Lee","year":"2009","journal-title":"Int J Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.biomaterials.2014.10.004","article-title":"LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways","volume":"37","author":"Chung","year":"2015","journal-title":"Biomaterials"},{"key":"B124","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1007\/s11095-015-1623-4","article-title":"Enhanced anti-angiogenic effect of low molecular weight heparin-bile acid conjugates by co-administration of a selective COX-2 inhibitor","volume":"32","author":"Kim","year":"2015","journal-title":"Pharm Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2012.10.001","article-title":"Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor","volume":"164","author":"Adulnirath","year":"2012","journal-title":"J Control Release"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3109\/03639045.2015.1122609","article-title":"Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models","volume":"42","author":"Alam","year":"2016","journal-title":"Drug Dev Ind Pharm"},{"key":"B127","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1016\/j.biomaterials.2014.04.050","article-title":"Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid","volume":"35","author":"Alam","year":"2014","journal-title":"Biomaterials"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.biomaterials.2012.11.020","article-title":"An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties","volume":"34","author":"Bae","year":"2013","journal-title":"Biomaterials"},{"key":"B129","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.01.058","article-title":"Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate)","volume":"86","author":"Alam","year":"2016","journal-title":"Biomaterials"},{"key":"B130","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jconrel.2014.12.015","article-title":"Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention","volume":"199","author":"Kim","year":"2015","journal-title":"J Control Release"},{"key":"B131","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biomaterials.2017.05.026","article-title":"A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway","volume":"139","author":"Choi","year":"2017","journal-title":"Biomaterials"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/bc800173m","article-title":"Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth","volume":"19","author":"Cho","year":"2008","journal-title":"Bioconjug Chem"},{"key":"B133","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2006.12.031","article-title":"Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate","volume":"118","author":"Lee","year":"2007","journal-title":"J Control Release"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s11095-009-9989-9","article-title":"Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells","volume":"26","author":"Lee","year":"2009","journal-title":"Pharm Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1021\/acs.bioconjchem.5b00133","article-title":"Size controlled heparin fragment\u2013deoxycholic acid conjugate showed anticancer property by inhibiting VEGF165","volume":"26","author":"Park","year":"2015","journal-title":"Bioconjug Chem"},{"key":"B136","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s11095-006-9190-3","article-title":"Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy","volume":"24","author":"Yu","year":"2007","journal-title":"Pharm Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10585-012-9461-9","article-title":"Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model","volume":"29","author":"Sudha","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/sj.bjc.6600307","article-title":"Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung","volume":"86","author":"Ono","year":"2002","journal-title":"Br J Cancer"},{"key":"B139","first-page":"3000","article-title":"Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice","volume":"53","author":"Thorpe","year":"1993","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-10-2476","article-title":"SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase\/syndecan-1 axis","volume":"17","author":"Ritchie","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"47848","DOI":"10.18632\/oncotarget.10292","article-title":"Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases","volume":"7","author":"Cassinelli","year":"2016","journal-title":"Oncotarget"},{"key":"B142","doi-asserted-by":"publisher","first-page":"111831","DOI":"10.1016\/j.ejmech.2019.111831","article-title":"Novel N-acetyl-glycol-split heparin biotin-conjugates endowed with anti-heparanase activity","volume":"186","author":"Esposito","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1096\/fj.07-8450com","article-title":"P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins","volume":"21","author":"Hostettler","year":"2007","journal-title":"Faseb j"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/glycob\/cwr053","article-title":"Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure\/activity relationship study","volume":"21","author":"Roy","year":"2011","journal-title":"Glycobiology"},{"key":"B145","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/glycob\/6.3.355","article-title":"Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties","volume":"6","author":"Lapierre","year":"1996","journal-title":"Glycobiology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3748\/wjg.v13.i3.457","article-title":"Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma","volume":"13","author":"Chen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/1097-0142(19820201)49:3%3C427::AID-CNCR2820490306%3E3.0.CO;2-6","article-title":"The influence of warfarin of levamisole on the incidence of metastases following local irradiation of a solid tumor","volume":"49","author":"Baker","year":"1982","journal-title":"Cancer"},{"key":"B148","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/(SICI)1097-0320(19971001)29:2%3C122::AID-CYTO4%3E3.0.CO;2-F","article-title":"Three-dimensional visualization and quantitation of fibrin in solid tumors by confocal laser scanning microscopy","volume":"29","author":"Biggerstaff","year":"1997","journal-title":"Cytometry"},{"key":"B149","first-page":"1217","article-title":"A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases","volume":"33","author":"Brown","year":"1973","journal-title":"Cancer Res"},{"key":"B150","first-page":"145","article-title":"The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastases in mice","volume":"37","author":"Carmel","year":"1977","journal-title":"Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00121197","article-title":"Ineffectiveness of inicarone, a fibrinolytic agent, alone or in combination with chemotherapeutic agents on spontaneously metastasizing murine tumours","volume":"1","author":"Dumont","year":"1983","journal-title":"Clin Exp Metastasis"},{"key":"B152","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ijc.2910390515","article-title":"Evidence for a warfarin-sensitive serum factor that participates in factor x activation by Lewis lung tumor cells","volume":"39","author":"Fasco","year":"1987","journal-title":"Int J Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF00578561","article-title":"Distribution and antitumoral activity of Adriamycin combined with warfarin in mice","volume":"5","author":"Ghersa","year":"1980","journal-title":"Cancer Chemother Pharmacol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2214\/ajr.111.1.42","article-title":"Clotting factors and metastasis formation","volume":"111","author":"Ketcham","year":"1971","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1242\/dmm.020933","article-title":"A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics","volume":"8","author":"Ocal","year":"2015","journal-title":"Dis Model Mech"},{"key":"B156","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0277-5379(85)90182-8","article-title":"Failure to warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells","volume":"21","author":"Lorenzet","year":"1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.taap.2008.01.008","article-title":"Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol","volume":"229","author":"Maeda","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1126\/science.162.3861.1493","article-title":"Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases","volume":"162","author":"Ryan","year":"1968","journal-title":"Science"},{"key":"B159","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00000658-196807000-00021","article-title":"Reduced incidence of spontaneous metastases with long-term coumadin* therapy","volume":"168","author":"Ryan","year":"1968","journal-title":"Ann Surg"},{"key":"B160","first-page":"2191","article-title":"Warfarin therapy as an adjunct to the surgical treatment of malignant tumors in mice","volume":"29","author":"Ryan","year":"1969","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1080\/15384047.2015.1078025","article-title":"Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis","volume":"16","author":"Alexander","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B162","doi-asserted-by":"publisher","first-page":"85291","DOI":"10.18632\/oncotarget.13300","article-title":"Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment","volume":"7","author":"Alexander","year":"2016","journal-title":"Oncotarget"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4161\/cbt.10.10.13236","article-title":"Use of dabigatran etexilate to reduce breast cancer progression","volume":"10","author":"DeFeo","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/jth.15663","article-title":"Thrombin cleavage of osteopontin initiates osteopontin\u2019s tumor-promoting activity","volume":"20","author":"Peraramelli","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B165","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1111\/jth.14604","article-title":"Rivaroxaban does not affect growth of human pancreatic tumors in mice","volume":"17","author":"Maqsood","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B166","doi-asserted-by":"publisher","first-page":"834472","DOI":"10.3389\/fphar.2022.834472","article-title":"Direct thrombin inhibitor dabigatran compromises pulmonary endothelial integrity in a murine model of breast cancer metastasis to the lungs; the role of platelets and inflammation-associated haemostasis","volume":"13","author":"Smeda","year":"2022","journal-title":"Front Pharmacol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2119\/molmed.2016.00214","article-title":"Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice","volume":"23","author":"Shi","year":"2017","journal-title":"Mol Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/1097-0142(197306)31:6%3C1392::AID-CNCR2820310614%3E3.0.CO;2-9","article-title":"Prophylaxis of metastases formation by unspecific immunologic stimulation associated with heparintherapy","volume":"31","author":"Kiricuta","year":"1973","journal-title":"Cancer"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1160\/TH09-01-0059","article-title":"Antimigratory and antimetastatic effect of heparin-derived 4\u201318 unit oligosaccharides in a preclinical human melanoma metastasis model","volume":"102","author":"Kenessey","year":"2009","journal-title":"Thromb Haemost"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/CAD.0000000000000141","article-title":"Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice","volume":"25","author":"Kim","year":"2014","journal-title":"Anticancer Drugs"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/life13091888","article-title":"Anti-inflammatory and anticancer effects of anticoagulant therapy in patients with malignancy","volume":"13","author":"Russo","year":"2023","journal-title":"Life (Basel)"},{"key":"B172","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ctrv.2007.02.004","article-title":"The effect of anticoagulants on cancer risk and survival: systematic review","volume":"33","author":"Tagalakis","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"B173","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-3982052\/v1","article-title":"Prognostic value of anticoagulants in resectable gastric cancer","author":"Wei","year":"2024"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B175","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1055\/s-0040-1709712","article-title":"The efficacy and safety of low molecular weight heparin administration to improve survival of cancer patients: a systematic review and meta-analysis","volume":"120","author":"Montroy","year":"2020","journal-title":"Thromb Haemost"},{"key":"B176","first-page":"369","article-title":"The influence of anticlotting agents on transplantation and growth of tumor tissue","volume":"16","author":"Goerner","year":"1931","journal-title":"J Lab Clin Med"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-05-3121","article-title":"L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest","volume":"66","author":"L\u00e4ubli","year":"2006","journal-title":"Cancer Res"},{"key":"B178","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and new applications of non-anticoagulant heparin","volume":"212","author":"Cassinelli","year":"2016","journal-title":"Int J Cardiol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real World - From the COMMAND VTE registry","volume":"83","author":"Sakamoto","year":"2019","journal-title":"Circ J"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamainternmed.2017.5512","article-title":"Association of warfarin use with lower overall cancer incidence among patients older than 50 years","volume":"177","author":"Haaland","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B183","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"B184","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/cancers14030703","article-title":"Direct oral anticoagulants are associated with superior survival outcomes than warfarin in patients with head and neck cancers","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B186","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0042-1758855","article-title":"Edoxaban, a factor Xa-specific direct oral anticoagulant, significantly suppresses tumor growth in colorectal cancer Colon26-inoculated BALB\/c mice","volume":"7","author":"Hiramoto","year":"2023","journal-title":"TH Open"}],"container-title":["Frontiers in Oral Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2024.1495942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T06:12:42Z","timestamp":1730873562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2024.1495942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":186,"alternative-id":["10.3389\/froh.2024.1495942"],"URL":"https:\/\/doi.org\/10.3389\/froh.2024.1495942","relation":{},"ISSN":["2673-4842"],"issn-type":[{"type":"electronic","value":"2673-4842"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"article-number":"1495942"}}